Search

Displaying results 1251 - 1260 of 10000 in total
  1. Target

    Tumor necrosis factor receptor superfamily member 18

    go.drugbank.com/bio_entities/BE0010519
    TargetHumans

    Receptor for TNFSF18. Seems to be involved in interactions between activated T-lymphocytes and endothelial cells and in the regulation of T-cell receptor-mediated cell death.

    Polypeptides: Tumor necrosis factor receptor superfamily member 18Synonyms: Activation-inducible TNFR family receptor
  2. Target

    Low-density lipoprotein receptor-related protein 6

    go.drugbank.com/bio_entities/BE0012061
    TargetHumans

    Component of the Wnt-Fzd-LRP5-LRP6 complex that triggers beta-catenin signaling through inducing aggregation of receptor-ligand complexes into ribosome-sized signalosomes (PubMed:11357136, PubMed:11448771

    Polypeptides: Low-density lipoprotein receptor-related protein 6
  3. Target

    Tyrosine-protein phosphatase non-receptor type 2

    go.drugbank.com/bio_entities/BE0012706
    TargetHumans

    Non-receptor type tyrosine-specific phosphatase that dephosphorylates receptor protein tyrosine kinases including INSR, EGFR, CSF1R, PDGFR. … May also regulate the hepatocyte growth factor receptor signaling pathway through dephosphorylation of the hepatocyte growth factor receptor MET. Also plays an important role in glucose homeostasis.

    Polypeptides: Tyrosine-protein phosphatase non-receptor type 2
  4. Target

    Tumor necrosis factor receptor superfamily member EDAR

    go.drugbank.com/bio_entities/BE0021253
    TargetHumans

    Receptor for EDA isoform A1, but not for EDA isoform A2. Mediates the activation of NF-kappa-B and JNK. May promote caspase-independent cell death

    Polypeptides: Tumor necrosis factor receptor superfamily member EDARSynonyms: EDA-A1 receptor, Ectodysplasin-A receptor
  5. Target

    T cell receptor beta variable 6-5

    go.drugbank.com/bio_entities/BE0021562
    TargetHumans

    V region of the variable domain of T cell receptor (TR) beta chain that participates in the antigen recognition (PubMed:24600447).

    Polypeptides: T cell receptor beta variable 6-5
  6. Drug

    Acolbifene

    go.drugbank.com/drugs/DB16080
    Investigational

    Acolbifene is under investigation in clinical trial NCT01452373 (Dehydroepiandrosterone (DHEA) + Acolbifene Against Vasomotor Symptoms (Hot Flushes) in Postmenopausal Women).

  7. Drug

    Calcium threonate

    go.drugbank.com/drugs/DB11168
    ApprovedWithdrawn

    Therapeutic efficacy of calcium threonate in reducing was studied and investigated due to the hypothesis that it may play a role in the mineralization process through its positive action on vitamin C. … The most common form is calcium L-threonate, or (2R,3S)-2,3,4-trihydroxy butyric acid calcium [A27266].

    Mixtures: Se-Vate 21/7, Se-Care Conceive
  8. Drug

    Ziritaxestat

    go.drugbank.com/drugs/DB15403
    Investigational

    Ziritaxestat is under investigation in clinical trial NCT03798366 (A Clinical Study to Test How Effective and Safe GLPG1690 is for Patients With Systemic Sclerosis).

  9. Drug

    Taprenepag

    go.drugbank.com/drugs/DB12623
    Investigational

    Taprenepag has been used in trials studying the treatment of Ocular Hypertension and Glaucoma, Open-Angle.

    Categories: Receptors, Prostaglandin E, EP2 Subtype, agonists
  10. Drug

    Calcium ascorbate

    go.drugbank.com/drugs/DB14483
    ApprovedNutraceutical

    Mixtures: Supplements De Vitamines Et Mineraux, Se-Vate 21/7